Comparison of Split versus Subunit Seasonal Influenza Vaccine in Korean Children over 3 to under 18 Years of Age
- Author:
Seah KANG
1
;
Dong Ho KIM
;
Byung Wook EUN
;
Nam Hee KIM
;
Eun Kyeong KANG
;
Byong Sop LEE
;
Yun Kyung KIM
Author Information
- Publication Type:Original Article
- Keywords: Influenza vaccine; Influenza; Safety; Children
- MeSH: Adolescent; Child; Hemagglutinins; Herpesvirus 1, Cercopithecine; Humans; Influenza Vaccines; Influenza, Human; Korea; Seasons; Seroconversion; Vaccines; Vaccines, Subunit
- From:Pediatric Infection & Vaccine 2019;26(3):161-169
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: This study was conducted to compare immunogenicities and reactogenicities of the trivalent inactivated subunit influenza vaccine and split influenza vaccine in Korean children and adolescents.METHODS: In total, 202 healthy children aged 36 months to <18 years were enrolled at six hospitals in Korea from October to December 2008. The subjects were vaccinated with either the split or subunit influenza vaccine. The hemagglutinin inhibition antibody titers against the H1N1, H3N2, and B virus strains were measured, and the seroconversion rates, seroprotection rates, and geometric mean titers were calculated. All subjects were observed for local and systemic reactions.RESULTS: Both the split and subunit vaccine groups had similar seroprotection rates against all strains (95.9%, 94.9%, 96.9% vs. 96.0%, 90.9%, and 87.9%). In children aged 36 to <72 months, the seroprotection rates were similar between the two vaccine groups. In children aged 72 months to <18 years, both vaccines showed high seroprotection rates against the H1N1, H3N2, and B strain (98.4%, 98.4%, 98.4% vs. 97.0%, 95.5%, and 91.0%), but showed relatively low seroconversion rates (39.1%, 73.4%, 35.9% vs. 34.3%, 55.2%, and 38.8%). There were more local and systemic reactions in the split vaccine group than in the subunit vaccine group; however, no serious adverse reactions were observed in both groups.CONCLUSIONS: Both the split and subunit vaccines showed acceptable immunogenicity in all age groups. There were no serious adverse events with both vaccines.
